Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company OncoSynergy Inc.
DescriptionHumanized mAb against integrin beta (1;CD29)
Molecular Target Integrin beta(1) (CD29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today